World Vaccine Congress Europe 2026

A vaccine community on the way back

My takeaways from three days at RAI Amsterdam, and an independent report for those who could not attend.

Three days at RAI Amsterdam — a workshop day on 19 October and the conference on 20–21 October 2026 — left me with one clear impression: the vaccine community is on the way back.

The mood was noticeably more positive than last year, and conversations looked forward rather than back. The congress's Net Promoter Score (NPS) rose from 27 to 36. The recovery after COVID-19 is not complete, and funding for both early- and late-stage development is still behind, especially for endemic and bacterial vaccines. Vaccine hesitancy also remains a challenge the whole sector needs to work on: scientific progress only pays off if public trust and vaccination uptake are rebuilt.

  • 280speakers
  • 220+sessions in 14 tracks
  • 64countries
  • 36NPS (27 in 2025)

Figures from the organiser's post-event report (Terrapinn).

Ten signals from Amsterdam

The overall picture: the science is ready faster than manufacturing, delivery and financing.

  1. Platform readiness is a CMC asset. Released cell banks, generic processes, qualified facilities and product-agnostic quality control are what make the 100-day mission possible.
  2. The Bundibugyo outbreak tested the system in real time, with several candidates on different platforms moving forward.
  3. mRNA influenza has reached the market, and pandemic H5 vaccines have moved into Phase 3.
  4. Combination vaccines are an economic problem as much as a technical one. Payer value and programmatic fit decide which combinations get built.
  5. Correlates of protection are under pressure, making standardised, multiplexed assays strategic infrastructure.
  6. Formulation and thermostability now set products apart.
  7. Tuberculosis and bacterial vaccines are approaching key readouts, but remain under-funded.
  8. Vaccination against highly pathogenic avian influenza in poultry is now EU policy in practice; trade acceptance is the open question.
  9. AI is entering GMP through regulation, not hype, with the draft EU GMP Annex 22 and FDA guidance.
  10. Capacity without products fails. Sustainable demand and process economics decide whether a facility survives.

What the full report covers

  • Seven key themes, from platform-based chemistry, manufacturing and controls (CMC) to pandemic preparedness and regulation, each with Almira Biotech's view on what it means in practice.
  • What the signals mean for developers, contract development and manufacturing organisations (CDMOs), investors and funders.
  • An overview of the sessions and speakers reviewed.

Request the report

Would you like a copy of the full report (13 pages, PDF)? Send me an email or a direct message on LinkedIn, and I will email it to you.

Request the report by email

Your email address is only used to send the report.

This is an independent summary by Almira Biotech Consultancy. It is not affiliated with or endorsed by Terrapinn, the World Vaccine Congress or the presenters. Data and claims are reported as presented and have not been independently verified.